Founded in 2019 by Narayanan Venkatasubramanian, Shridhar Narayanan, Anand Budni, and Amit Mahajan, Peptris Technologies applies proprietary AI models to generate novel chemical entities (NCEs) and forecast critical drug-development metrics early in the pipeline. The platform targets persistent inefficiencies in pre-clinical drug discovery, aiming to shorten timelines, cut costs, and reduce scientific uncertainty. Peptris operates on a B2B model, licensing assets and co-developing programs with pharmaceutical, biotech, and select FMCG partners. Its therapeutic focus spans rare diseases, inflammation, oncology, and women’s health, and it has already identified multiple NCEs as well as repurposing and rescue candidates moving toward clinical development. Over the next 24 months, the company intends to advance its current programs to clinical readiness, initiate several new NCE projects, and scale teams across biology, chemistry, data science, and AI. While revenue figures have not been disclosed, the recent funding underscores investor confidence in the platform’s commercial potential and pipeline breadth.

Total raised

$9M

Funding rounds

2

Latest round

Seed

Latest activity

Dec 2023